(Credit: © Saiful52 - stock.adobe.com)
In a Nutshell
- A viral protein called mgG-2, long dismissed as unimportant, turns out to help HSV-2 escape infected cells and spread toward the nervous system in mice.
- A vaccine made from that same protein protected 93.7 percent of mice from a lethal dose of the virus and sharply cut its spread into nerve and spinal-cord tissue.
- The protein’s natural sugar coating is what makes it work: stripping away both main sugar groups dropped survival to 43.8 percent.
For decades, the hunt for a herpes vaccine has followed the same frustrating script: strong results in animals, then failure once the shots reach people. A new study flips that script by pointing at a viral protein most researchers had written off. This protein helps the virus spread from infected tissue into the nervous system, yet when it becomes the main ingredient in a vaccine, it appears to block the very route it normally opens.
Herpes simplex virus type 2, known as HSV-2, infected more than 500 million people aged 15 to 49 worldwide, according to a 2016 estimate cited in the paper. It causes genital herpes and hides permanently in nerve clusters near the base of the spine, flaring up now and then to trigger outbreaks or to spread silently. In severe cases, it can reach the spinal cord and brain. Despite years of effort, no vaccine has been approved.
Published in the journal PLOS Pathogens, the new research zeroes in on a protein that had been sitting in the background: membrane-associated glycoprotein G, or mgG-2 for short. Scientists knew it existed but mostly ignored it, because the virus can still grow in a lab dish without it. This work argues that mgG-2 matters far more inside a living body, where it helps the virus escape infected cells and enter the nervous system. A carefully made version of that same protein, with its natural sugar coating left on, protected mice from a deadly dose of the virus.
A Viral Protein That Helps Herpes Invade the Nerves
To find out what mgG-2 actually does inside a living animal, researchers built a version of HSV-2 with the gene for the protein switched off. They then infected two strains of lab mice through the genital route, mimicking how people catch the virus, and tracked where it traveled.
Normal HSV-2 followed a grim, predictable path. It multiplied in the vaginal lining, moved into the blood and nearby lymph nodes, reached the nerve clusters at the base of the spine, climbed into the spinal cord, and killed the animals. Mice given the altered virus, the one missing mgG-2, had a very different outcome. It still copied itself in vaginal tissue, sometimes as heavily as the normal virus, but it barely spread to the nervous system. In one mouse strain, every animal survived. In a more vulnerable strain, 86 percent lived, compared with none of the mice that got the normal virus. Nerve and spinal-cord tissue from the altered-virus group showed no detectable infectious virus. The authors called that drop “the most important finding which explains the high survival rate” of the animals.
Without mgG-2, the virus seems to get stuck. It can still replicate, but it struggles to break free from the surface of infected cells and into surrounding tissue and fluid, a step it needs to reach nerve endings and begin its journey inward.
Why This Herpes Vaccine Only Works With Its Sugar Coating
Alongside the infection experiments, the team tested mgG-2 as a vaccine ingredient. They made a lab version of the protein, gave it to mice, and then exposed those mice to a dose of normal HSV-2 strong enough to kill unprotected animals. Mice that received the full protein, sugar coating and all, did well: 93.7 percent survived two weeks after infection, and viral spread into their nerve clusters and spinal cords dropped sharply.
Then came the question with real weight for vaccine makers: what happens without the sugars? Proteins made by cells come wrapped in intricate sugar structures, and those structures can steer how the immune system reacts. Researchers built five versions of the vaccine protein, one fully coated, one stripped of all sugars, and three missing specific sugar types.
Stripping away both main sugar groups at once gutted the protection. Survival fell to 43.8 percent, and surviving mice carried far more virus in nerve and spinal cord tissue than did the fully coated group. Removing just one type of sugar at a time did little harm. Damage showed up only when both were gone together.
How the Sugar Coating Shapes the Body’s Defense
To see why the coating mattered, the team looked inside the immune systems of vaccinated mice. A fully coated protein elicited a strong response from CD4-positive T cells, immune cells that coordinate and boost the body’s defenses. Those cells pumped out a pattern of signaling molecules associated with a response called Th1 activation, which tends to work well against herpes viruses. Mice given the stripped protein mounted a weaker version of the same reaction.
Sugar structures may help the immune system recognize and process the protein, aiming the response at its most protective parts. There was another twist. When mice received the sugar-stripped vaccine, their antibodies reacted less strongly to the fully coated protein, meaning the shot had trained them against something slightly different from what the real virus looks like.
What This Herpes Vaccine Discovery Could Mean
Earlier vaccine attempts went after two other proteins, gB-2 and gD-2, that the virus uses to force its way into cells. Blocking entry seemed logical, but those candidates fell short in human trials, partly because the antibodies they produced failed to hit key human targets they had hit in animals. Going after mgG-2 flips the approach. Instead of guarding the front door, a vaccine against this protein would target the step where the virus escapes a cell and heads for the nerves.
One detail strengthens the case. Among more than 2,400 clinical HSV-2 samples in an earlier study, only two lacked a working copy of mgG-2. That near-universal presence points to strong evolutionary pressure keeping the protein in place, which also makes it a stable target a vaccine could be built around.
There is a catch worth flagging for drug developers. Because the sugar coating is what makes the vaccine effective, how the protein gets manufactured could strongly affect how well it works. Different cell systems add different sugar patterns to the same protein, and those differences may change how well a shot performs. The authors urge close attention to production methods in any future effort.
Mouse studies sit early on a long road, and plenty could still go wrong in people. Still, for a field stuck at the same wall for years, a protein that both fuels the disease and can be turned back against it offers researchers a fresh lead to pursue.
Disclaimer: This article describes early-stage research conducted entirely in mice. Results in animals have repeatedly failed to carry over to humans in HSV-2 vaccine trials, and no herpes vaccine has been approved. Nothing here is medical advice or a description of an available treatment. Anyone with questions about herpes prevention or care should consult a licensed healthcare provider.
Paper Notes
Limitations
Several limitations shape how far these results reach. All of the work was done in mice, and the authors stress that animal models have not reliably predicted outcomes in human HSV-2 vaccine trials, in part because the virus uses human-specific tricks to evade the immune system that cannot be replicated in animals. Researchers were also unable to pin down the exact spots on mgG-2 that the immune system’s B cells and T cells latch onto, so they could not measure how each individual sugar structure shapes the response. Because the sugar-free versions of the vaccine protein were made using enzymes, some sugars, especially the harder-to-remove O-linked kind, may have lingered on part of the protein. Those leftover sugars could have propped up the partial protection seen in the stripped group, which means that group’s performance may be overstated rather than understated. An attempt to make a fully sugar-free version in bacteria failed entirely, suggesting that sugars are needed for the protein to fold and be processed correctly. Finally, viral spread was tracked only in tissues tied to the known course of genital infection in mice, so how the altered virus behaves elsewhere in the body remains unknown.
Funding and Disclosures
Grants from Sweden’s innovation agency Vinnova (2020-03108) and the ALF Foundation of Sahlgrenska University Hospital (ALFGbg-1006865 and ALFGbg-716041), awarded to R.N., T.B., and J.L., supported the study. Funders had no role in the study’s design, data collection and analysis, the decision to publish, or preparation of the manuscript. Four authors, J.L., L.G., S.G., and T.B., are developing an HSV-2 vaccine through a company called Simplexia AB, though they state that no financial contributions to this specific work came from that company. All other authors reported no conflicts of interest. The authors also disclosed using generative AI (ChatGPT-5.3, OpenAI) for language refinement and grammar correction, and state that no substantial text or original ideas were generated with it.
Publication Details
Authors: Ebba Könighofer, Carolina Gustafsson, Lindvi Gudmundsdotter, Ekaterina Mirgorodskaya, Jonas Nilsson, Maria Ekblad, Beata Adamiak, Eva Jennische, Stefan Lange, Edward Trybala, Staffan Görander, Tomas Bergström, Jan-Åke Liljeqvist, and Rickard Nordén. The authors are affiliated with the Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; the Department of Clinical Microbiology, Sahlgrenska University Hospital; Simplexia AB; and the Proteomics Core Facility and Department of Medical Biochemistry and Cell Biology, Sahlgrenska Academy, University of Gothenburg, all in Sweden.
Journal: PLOS Pathogens
Paper Title: “Glycoprotein G enables HSV-2 neuroinvasion and provides protection as a glycosylated vaccine antigen”
Published: July 9, 2026
